Document:

Intellectual Property Assignment Agreement

 EXHIBIT 10.5 
 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF

 DENOTED WITH “***” 
 INTELLECTUAL PROPERTY ASSIGNMENT 
 AGREEMENT 
 BETWEEN 
 QLT USA, INC.

 AND 
 ARIUS TWO,
INC. 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page
	 ARTICLE I DEFINITIONS
	  	1
			
	 Section 1.01
	  	 Definitions
	  	1
	 Section 1.02
	  	 Defined Terms
	  	6
	 Section 1.03
	  	 No Amendment to License Definitions
	  	6
		
	 ARTICLE II PURCHASE, SALE, ASSIGNMENT, AND LICENSE
	  	6
			
	 Section 2.01
	  	 Purchase and Sales
	  	6
	 Section 2.02
	  	 Know-How License
	  	7
	 Section 2.03
	  	 Consideration
	  	7
	 Section 2.04
	  	 Termination of License Agreement
	  	7
	 Section 2.05
	  	 Expenses
	  	7
		
	 ARTICLE III PATENT INFRINGEMENT
	  	8
			
	 Section 3.01
	  	 Infringement Claimed by Third Parties
	  	8
	 Section 3.02
	  	 Indemnification of Seller
	  	8
	 Section 3.03
	  	 Indemnification of Buyer
	  	8
	 Section 3.04
	  	 Payment of Costs and Expenses
	  	8
	 Section 3.05
	  	 Termination of Obligations
	  	9
		
	 ARTICLE IV CONFIDENTIALITY
	  	9
			
	 Section 4.01
	  	 Confidentiality
	  	9
	 Section 4.02
	  	 Disclosure of Agreement
	  	9
		
	 ARTICLE V REPRESENTATIONS AND WARRANTIES
	  	10
			
	 Section 5.01
	  	 Corporate Power
	  	10
	 Section 5.02
	  	 Due Authorization
	  	10
	 Section 5.03
	  	 Binding Obligation
	  	10
	 Section 5.04
	  	 Ownership of Purchased Assets
	  	11
	 Section 5.05
	  	 Patent Proceedings
	  	11
	 Section 5.06
	  	 Legal Proceedings
	  	11
	 Section 5.07
	  	 Limitation on Warranties
	  	11
	 Section 5.08
	  	 Limitation of Liability
	  	11
		
	 ARTICLE VI COVENANTS
	  	12
			
	 Section 6.01
	  	 Access to Books and Records
	  	12

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

					
	 Section 6.02
	  	 Commercially Reasonable Efforts
	  	12
	 Section 6.03
	  	 Compliance
	  	12
	 Section 6.04
	  	 Further Actions
	  	12
		
	 ARTICLE VII DELIVERIES
	  	13
			
	 Section 7.01
	  	 Deliveries By Seller
	  	13
	 Section 7.02
	  	 Deliveries By Buyer
	  	13
		
	 ARTICLE VIII MISCELLANEOUS
	  	14
			
	 Section 8.01
	  	 Governing Law
	  	14
	 Section 8.02
	  	 Waiver
	  	14
	 Section 8.03
	  	 Severability
	  	14
	 Section 8.04
	  	 Notices
	  	14
	 Section 8.05
	  	 Independent Contractors
	  	15
	 Section 8.06
	  	 Rules of Construction
	  	15
	 Section 8.07
	  	 Publicity
	  	15
	 Section 8.08
	  	 Entire Agreement; Amendment
	  	15
	 Section 8.09
	  	 Headings
	  	16
	 Section 8.10
	  	 Waiver of Jury Trial
	  	16
	 Section 8.11
	  	 Counterparts
	  	16
	 Section 8.12
	  	 Assignment
	  	16

  

					
	 Exhibit A
	 	-	  	BEMA Patent Rights
	 Exhibit B
	 	-	  	Guaranty
	 Exhibit C
	 	-	  	Patent and Trademark Assignment Agreement
	 Exhibit D
	 	-	  	Patent and Trademark Security Agreement
	 Exhibit E
	 	-	  	Secured Promissory Note
	 Exhibit F
	 	-	  	Security Agreement
	 Exhibit G
	 	-	  	Termination Agreement

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT 
 This Intellectual Property Assignment Agreement (the “Agreement”) is made as of September 5, 2007 (the “Effective Date”) by and
between QLT USA, Inc. (formerly Atrix Laboratories, Inc.), a Delaware corporation with its principal office at 2579 Midpoint Drive, Fort Collins, CO 80525-4417 (“Seller”), and Arius Two, Inc., a Delaware corporation with its principal
office at 2501 Aerial Center Parkway, Suite 205, Morrisville, NC 27560 (“Buyer”). Seller and Buyer are sometimes referred to collectively herein as the “Parties” or singly as a “Party.” 
 RECITALS 
 WHEREAS, Seller and
Arius Pharmaceuticals, Inc. (“Arius”) entered into that certain License Agreement dated May 27, 2004, as amended July 14, 2005 and August 2, 2006 (as amended, the “License Agreement”); and 
 WHEREAS, Seller has agreed to sell to Buyer, and Buyer has agreed to purchase from Seller the BEMA assets related specifically to the United
States. 
 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants and agreements contained herein, the
Parties hereto, intending to be legally bound, do hereby agree as follows: 
 AGREEMENT 
 ARTICLE I 
 DEFINITIONS

 Section 1.01 Definitions. The following terms as used in this Agreement shall have the meaning set forth below:

 “Affiliate” means an individual, trust, business trust, joint venture, partnership, corporation, association or any other
entity which owns, is owned by or is under common ownership with, a Party. For the purposes of this definition, the term “owns” (including, with correlative meanings, the terms “owned by” and “under common ownership
with”) as used with respect to any Party, shall mean the possession (directly or indirectly) of more than 50% of the outstanding voting securities of a corporation or comparable equity interest in any other type of entity. 
 “Applicable Laws” means all applicable laws, rules, regulations and guidelines that may apply to the performance of either Party’s
obligations under this Agreement. 
 “Assumed Liabilities” means all obligations and liabilities arising out of Buyer’s
ownership of the Purchased Assets, whether arising prior to or after the Effective Date; except for such obligations and liabilities for which Seller is obligated to indemnify Buyer under Section 3.03 of this Agreement. 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 “BEMA” means Seller’s proprietary bioerodible, mucoadhesive multi-layer polymer
film. 
 “Claims” shall mean and include all past, present and future disputes, claims, controversies, demands, rights,
obligations, liabilities, actions and causes of action of every kind and nature. 
 “Combination Product” means a Worldwide
Product (as defined below) that is sold together with any other products and/or services at a unit price, whether packaged together or separately with another pharmaceutical product or other device, equipment, instrumentation, or other components
(other than solely containers or packaging exclusively for the Worldwide Product). 
 “Commercially Reasonable Efforts”
shall mean, except as otherwise explicitly set forth in this Agreement, those efforts consistent with the exercise of prudent scientific and business judgment, as applied to products having comparable market potential within the relevant product
lines of that Party and generally accepted practices in the pharmaceutical industry. “Comparable market potential” shall be fairly determined by a Party in good faith and without limitation may be based upon market size, price,
competition, patent rights, product liability issues and general marketing parameters. 
 “Competent Authorities” means,
collectively, all governmental entities, foreign or domestic, responsible for the regulation of medicinal products intended for human use. 
 “Confidential Information” means any confidential or proprietary information of a Party, whether in oral, written, graphic or electronic form. Confidential Information shall not include any information which the receiving
Party can prove by competent evidence: 
 (a) is now, or hereafter becomes, through no act or failure to act on the part of
the receiving Party, generally known by or available to the public; 
 (b) is known by the receiving Party at the time of
receiving such information, as evidenced by its written records maintained in the ordinary course of business; 
 (c) is
hereafter furnished to the receiving Party by a Third Party, as a matter of right and without restriction on disclosure; 
 (d) is independently developed by the receiving Party, as evidenced by its written records maintained in the ordinary course of business, without knowledge of, and without the aid, application or use of, the disclosing Party’s
Confidential Information; or 
 (e) is the subject of a written permission to disclose provided by the disclosing Party.

  

 2 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 “Control” means the possession of the ability to assign to Buyer as provided for
herein without violating the terms of any agreement or other arrangement with any Third Party. 
 “Encumbrance” means any
lien, pledge, hypothecation, mortgage, security interest, encumbrance, equitable interest, preference, right of possession, lease, tenancy, license, proxy, covenant, order, option, right of first refusal or preemptive right, whether arising out of
an obligation to pay any taxes or otherwise. 
 “BEMA Know-How” means all Know-How related to BEMA or any Product which is
under the Control of Seller as of the Effective Date, including, but not limited to, data and documentation of clinical trials, pharmacological, toxicological, clinical, assay, control, and manufacturing data, techniques, processes, methods, or
systems, and any other information relating to BEMA, excluding the BEMA Patent Rights. 
 “Marks” means all right, title,
and interest in “BEMA” or any additional trademarks or service marks owned by Seller with respect to the BEMA Technology, alone or accompanied by any logo or design and any non-English language equivalents in figure, sound or meaning,
whether registered or not, including but not limited to any and all such rights in the Territory existing solely under common law, statute, or similar bases not requiring explicit government notice or registration. 
 “BEMA Patent Rights” means all Patent Rights claiming BEMA or any Improvement, or which are necessary, useful, or appropriate to
develop, manufacture, or commercialize Products, and under the Control of Seller as of the Effective Date, which shall include but not be limited to the patents and patent applications listed on Exhibit A. 
 “BEMA Technology” means the BEMA Patent Rights and the BEMA Know-How. 
 “Books and Records” means, in whatever media, any and all books and records, reports and accounts and data in connection with or related
to any Product, BEMA Technology, or Marks, or any research, development, or other activities primarily related to the foregoing (including but not limited to those related to filing, prosecution, and/or maintenance of the BEMA Patent Rights).

 “US Patent Term” means, on a Product-by-Product basis, the period of time ending on the expiration of the last to expire
of the BEMA Patent Rights covering such Product in the Territory. 
 “Ex-US Purchase Agreement” means that certain
Intellectual Property Assignment Agreement, dated August 2, 2006, between the Parties. 
 “Ex-US BEMA Patent Rights”
means all Patent Rights assigned to Buyer pursuant to the Ex-US Purchase Agreement. 
 “Ex-US Product” means individually
and collectively any product which would infringe one or more valid claims of the Ex-US BEMA Patent Rights. 
  

 3 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 “Territory” means the United States. 
 “FDA” means the Food and Drug Administration, the governmental entity responsible in the United States for the regulation of medicinal
products intended for human use. 
 “GAAP” means generally accepted accounting principles of the United States consistently
applied on a basis consistent throughout the periods indicated and consistent with each other. 
 “Governmental Approval”
means all permits, licenses and authorizations, including but not limited to, import permits and Marketing Authorizations required by any Competent Authority as a prerequisite to the manufacturing, marketing or selling of the Product for human
therapeutic use. 
 “Guaranty” means that certain Guaranty to be executed by BioDelivery Sciences International, Inc.
(“BDSI”), owner of all of the outstanding capital stock of Buyer, in the form attached hereto as Exhibit B. 
 “Improvement” means any and all developments, inventions or discoveries directly relating to the BEMA Technology developed or acquired by, or under the Control of, a Party at any time prior to or
following the Effective Date and shall include, but not be limited to, such developments intended to enhance the safety and/or efficacy of any Product.  
 “Know-How” means all know-how, trade secrets, inventions, data, processes, techniques, procedures, compositions, devices, methods, formulas, protocols and information, whether or not patentable, which
are not generally publicly known, including, without limitation, all chemical, biochemical, toxicological, and scientific research information, whether in written, graphic or video form or any other form or format. 
 “Marketing Authorization” means all necessary and appropriate regulatory approvals, including but not limited to, variations thereto,
and Pricing and Reimbursement Approvals to put a Product on the market in a particular jurisdiction. 
 “Net Sales” means
the gross amounts invoiced by Buyer, its Affiliates or sublicensees for sales of the Worldwide Product by Buyer, its Affiliates, or its sublicensees, as applicable, to a Third Party in a bona fide arm’s length transaction, less the following
items: ***. Net Sales shall not include any sales or transfers of Worldwide Products by Buyer or its Affiliates to Affiliates or sublicensees pursuant to manufacturing or distribution agreements where such Affiliate or sublicensee will
ultimately sell such Worldwide Product and such amounts received in connection with sale will be included in Net Sales. 
 A Worldwide
Product shall be considered sold when billed out or invoiced. Components of Net Sales shall be determined in the ordinary course of business in accordance with historical practice and using the accrual method of accounting in accordance with GAAP.

 In the event Buyer transfers Worldwide Product to a Third Party in a bona fide arm’s length transaction, for consideration, in whole
or in part, other than cash or to a Third Party in 

  

 4 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 
other than a bona fide arm’s length transaction, the Net Sales price for such Worldwide Product shall be deemed to be the standard invoice price then
being invoiced by Buyer in an arms length transaction with similar customers. The Net Sales of a Combination Product shall be calculated as if the invoiced sales price for a Product included within the Combination Product is ***. In the event
that Buyer includes a Worldwide Product as part of a single bundled sale of separate products with separately stated prices, the Net Sales attributable to such Worldwide Product shall be the higher of ***. 
 “Patent and Trademark Assignment Agreement” means the Patent and Trademark Assignment Agreement executed by Seller in the form attached
hereto as Exhibit C. 
 “Patent and Trademark Security Agreement” means that certain Patent and Trademark
Security Agreement between Buyer and Seller in the form attached hereto as Exhibit D. 
 “Patent Rights” means
all rights under patents and patent applications, and any and all patents issuing therefrom (including utility, model and design patents and certificates of invention), together with any and all substitutions, extensions (including supplemental
protection certificates), registrations, confirmations, reissues, divisionals, continuations, continuations-in-part, re-examinations, renewals and foreign counterparts of the foregoing, and all improvements, supplements, modifications or additions.

 “Pricing and Reimbursement Approvals” means any pricing and reimbursement approvals which may or must be obtained before
placing a Product on the market in a particular jurisdiction. 
 “Product” means a Product, as defined in the License
Agreement, excluding an Ex-US Product. 
 “Purchased Assets” means (i) the Marks, (ii) BEMA Technology,
(iii) Books and Records, (iv) all Government Approvals (as defined in the License Agreement) and appropriate correspondence, clearance or transfer letters, or any other form of authorization, license, permit, or the like from regulatory
authorities with respect to Government Approvals, to the extent not previously assigned to Buyer under the License Agreement, and (v) any and all benefits, privileges, causes of action, and remedies relating to any of the foregoing, whether
before or hereafter accrued, including, without limitation, all rights in, to and under applications for, filings, registrations or renewals, and rights to apply for, file, register, maintain, extend or renew any of the foregoing and the right to
bring actions for past, present or future infringement of or otherwise enforce any of the foregoing and to settle and retain the proceeds of such actions (including, without limitation, all causes of actions relating to any of the foregoing, claims
and demands or other rights accruing with respect to any of the foregoing, or arising from any infringement of the BEMA Technology and the Marks, before or after the Effective Date), and any and all other rights corresponding thereto throughout the
world. 
 “Secured Promissory Note” means that certain secured promissory note made by Buyer in favor of Seller in the form
attached hereto as Exhibit E, the terms and conditions of which are incorporated herein by reference. 
  

 5 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 “Security Agreement” means that certain Security Agreement between Buyer and Seller
in the form attached hereto as Exhibit F. 
 “Third Party” means any entity other than: (a) Seller,
(b) Buyer or (c) an Affiliate of Seller or Buyer. 
 “United States” or “US” means the United States of
America, its territories and possessions, including the Commonwealth of Puerto Rico. 
 “Worldwide Product” means,
collectively, all Ex-US Products and Products. 
 Section 1.02 Defined Terms. Each of the following terms is defined in
the Section set forth opposite such term below: 
  

			
	 Agreement
	  	Preamble
	 Arius
	  	Recitals
	 Assumed Liabilities
	  	Section 2.01
	 Buyer
	  	Preamble
	 CDC
	  	Recitals
	 Closing Cash Payment
	  	Section 2.03(a)
	 Effective Date
	  	Preamble
	 Indemnified Party
	  	Section 3.04
	 Indemnifying Party
	  	Section 3.04
	 License Agreement
	  	Recitals
	 Loss
	  	Section 3.02
	 Party(ies)
	  	Preamble
	 Purchase Price
	  	Section 2.03
	 Seller
	  	Preamble
	 Third Party Claim
	  	Section 3.01

 Section 1.03 No Amendment to License Definitions.
The definition of certain terms above which are also separately defined above shall not in any way alter, amend, or be used to interpret the definitions established under the License Agreement. 
 ARTICLE II 
 PURCHASE, SALE,
ASSIGNMENT, AND LICENSE 
 Section 2.01 Purchase and Sales. Subject to the terms and conditions set forth in this
Agreement, effective on the Effective Date, Seller hereby conveys, assigns, and transfers to Buyer, and Buyer hereby acquires from Seller, for the Purchase Price, free and clear of all Encumbrances, the Purchased Assets and shall assume, pay,
discharge, and perform all Assumed Liabilities. For a period of three months following the Effective Date, Seller will cooperate with Buyer, as reasonably requested by Buyer and at Buyer’s expense, which expense shall be commercially reasonable
and documented, in effecting the transfer of the Marks to Buyer and enabling Buyer to file registrations, applications therefor, or equivalent formal legal recognition of, or rights with respect to, the Marks in Buyer’s name in the Territory,
and Buyer shall own all right, title, and interest thereto in the Territory. 
  

 6 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 Section 2.02 Know-How License. To the extent any BEMA Know-How or Improvement
cannot be severed from Know-How related to technology or intellectual property other than BEMA Technology and assigned to Buyer as contemplated by this Agreement, Seller hereby grants to Buyer an exclusive, perpetual, royalty-free, fully-paid
license in the Territory, with rights of sublicense, under and to such Know-How and Improvements (to the extent not claimed in any BEMA Patent Rights and concerning or related to BEMA (and not any technology other than BEMA)) made, obtained, or
Controlled by Seller and related Books and Records to use, develop, market, advertise, promote, distribute, offer for sale, sell, export and import, manufacture, and have manufactured Products, provided that, following the expiration of the US
Patent Term, such license shall be non-exclusive, fully-paid, perpetual and royalty-free. 
 Section 2.03 Consideration.
As consideration for the Purchased Assets, Buyer shall pay to Seller total consideration of $7,000,000 (the “Purchase Price”). The Purchase Price shall be payable as follows: 
 (a) $3,000,000 (the “Closing Cash Payment”), by wire transfer of immediately available funds on the Effective Date to an account
designated by Seller; and 
 (b) $4,000,000, as evidenced by a secured promissory note, to Seller as follows: 
 (i) $2,000,000, within ten (10) business days after the initial Governmental Approval of a Product in the United States; and

 (ii) $2,000,000, the first time that cumulative Net Sales exceed $30,000,000. Such payment shall be made within 30 days
following the end of the calendar quarter during which cumulative Net Sales exceed such amount. 
 For the avoidance of doubt, each payment
referred to in this Section 2.03(b) shall be paid only once by Buyer and only be become due and payable at such time as the event described in the relevant subsection has occurred. 
 Section 2.04 Termination of License Agreement. Pursuant to the form of termination agreement attached hereto as Exhibit G (the
“Termination Agreement”), to be executed by Arius, Seller, and CDC prior to or as of the Effective Date, the License Agreement shall terminate, and be of no further force and effect, upon the assignment of all Purchased Assets to Buyer
pursuant to Section 2.01. 
 Section 2.05 Expenses. The Parties shall each bear their own costs and expenses
(including attorneys’ fees) incurred in connection with the negotiation and preparation of this Agreement and consummation of the transactions contemplated hereby. Buyer shall pay all documented costs associated with the perfection and
recording of the documents related to the assignment of the Purchased Assets. 
  

 7 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 ARTICLE III 
 PATENT INFRINGEMENT 
 Section 3.01 Infringement Claimed by Third Parties. In the
event a Third Party commences a judicial or administrative proceeding against a Party and such proceeding pertains to the BEMA Patent Rights or Marks (the “Third Party Claim”), or threatens to commence such a Third Party Claim, the Party
against whom such proceeding is threatened or commenced shall give prompt notice to the other Party. Buyer shall, using its choice of counsel and at its own cost and expense, defend any and all such Third Party Claims or proceedings with respect to
any of the Purchased Assets or the licensing of rights thereto by Seller to Arius, and Seller shall, at Buyer’ cost and expense, provide such assistance and cooperation to Buyer as may be reasonably requested by Buyer to defend any such Third
Party Claims. The above notwithstanding, without Seller’s prior written consent, which shall not be unreasonably withheld, Buyer may only settle any such claim so long as the terms of such settlement do not (a) impair Seller’s rights
hereunder, or (b) impose any costs directly or indirectly on Seller. 
 Section 3.02 Indemnification of
Seller. Buyer shall indemnify and hold Seller, its Affiliates, and their respective employees, directors and officers, harmless from and against any liabilities or obligations, damages, losses, claims, encumbrances, costs or expenses
(including attorneys’ fees) (any or all of the foregoing herein referred to as “Loss”) insofar as a Loss or actions in respect thereof occurs subsequent to the Effective Date and arises out of or is based upon (a) any claims that
the use, marketing, sale, promotion, distribution, manufacture, shipment or sale of a Product by Buyer, its sublicensees or Affiliates infringes the patent, trademark or proprietary right or any other published intellectual property right of a Third
Party (including any willful infringement); (b) Buyer’s or its sublicensees’ manufacture, development, marketing, use, handling, storage, sale, distribution or promotion of the Product or any demonstration samples; (c) any
product liability claim that is brought against Seller by any Third Party arising out of or related to any Product made or sold by Buyer, its Affiliates, or its sublicensees; (d) Buyer’s prosecution of a Third Party infringement claim,
(e) any Third Party Claim arising out of or related to the Purchased Assets; or (f) Buyer’s breach of its representations, warranties or covenants set forth in this Agreement; provided, however, Buyer shall not be required to
indemnify Seller for any Claim for which Seller is obligated to indemnify Buyer under Section 3.03. 
 Section 3.03
Indemnification of Buyer. Seller shall indemnify and hold Buyer, its Affiliates, and their respective employees, directors, officers, and licensees harmless from and against any Losses insofar as a Loss or actions in respect thereof
arises out of or is based upon Seller’s breach of any of its representations, warranties, or covenants set forth in this Agreement. 
 Section 3.04 Payment of Costs and Expenses. Upon the indemnifying party’s (the “Indemnifying Party”) receipt of a reasonably detailed invoice setting forth the reasonable, documented costs and expenses
incurred by the indemnified party (the “Indemnified Party”) with 

  

 8 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 
respect to matters for which the Indemnifying Party is obligated to reimburse or indemnify the Indemnified Party pursuant to Section 3.01, 3.02, or
3.03, the Indemnifying Party shall pay such costs and expenses within 30 days. 
 Section 3.05 Termination of
Obligations. Upon the assignment or sale of the Purchased Assets to Seller, an Affiliate thereof, or any Third Party as a result of Seller’s exercise of its rights under the Security Agreement or Patent and Trademark Security
Agreement, Buyer shall have no further obligations under Sections 3.01 and 3.02 solely with respect to any Third Party Claims or Losses that arise out of, or are caused by, the use of the Purchased Assets by Seller, its Affiliates or any Third Party
assigned the Purchased Assets as a result of the exercise of Seller’s rights under the Security Agreement or Patent and Trademark Security Agreement, any assignee of any of the foregoing, or licensees of any of the foregoing after the date of
such assignment or sale. 
 ARTICLE IV 
 CONFIDENTIALITY 
 Section 4.01 Confidentiality. For a period of *** years
after the Effective Date, each Party shall maintain all Confidential Information of the other Party as confidential and shall not disclose any such Confidential Information to any Third Party or use any such Confidential Information for any purpose,
except (a) as expressly authorized by this Agreement, (b) as required by law, rule, regulation or court order (provided that the disclosing Party shall first notify the other Party, shall use Commercially Reasonable Efforts to obtain
confidential treatment of any such information required to be disclosed, and shall disclose only the minimum information required to be disclosed in order to comply), or (c) to its Affiliates, sublicensees, employees, agents, consultants and
other representatives to accomplish the purposes of this Agreement, so long as such persons are under an obligation of confidentiality no less stringent than as set forth herein, provided that information concerning any of the Purchased Assets (or
rights licensed under Section 2.02) shall be deemed the Confidential Information of Buyer. Each Party may use such Confidential Information only to the extent required to accomplish the purposes of this Agreement. Each Party shall use at least
the same standard of care as it uses to protect its own Confidential Information (but not less than a reasonable standard of care) to ensure that its Affiliates, employees, agents, consultants and other representatives do not disclose or make any
unauthorized use of the other Party’s Confidential Information. Each Party shall promptly notify the other Party upon discovery of any unauthorized use or disclosure of the other Party’s Confidential Information. 
 Section 4.02 Disclosure of Agreement. Neither Party shall release to any Third Party or publish in any way any non-public information
with respect to the terms of this Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld. Notwithstanding the foregoing a Party may disclose the terms of this Agreement to potential
investors, lenders, investment bankers and other financial institutions of its choice solely for purposes of financing the business operations of such Party, or, in the case of Buyer, to any prospective or actual sublicensee, manufacturer, marketing
or other corporate partner, acquirer, acquisition target, or existing investor or lender of a Party or any Affiliate thereof, 

  

 9 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 
including but not limited to Meda AB, CDC, or any future licensee of Arius Two or Arius with respect to any portion of the Purchased Assets; provided such
Party only discloses such information under conditions of confidentiality on terms substantially similar to those contained in this Article IV. Nothing contained in this paragraph shall prohibit either Party from filing this Agreement as
required by the rules and regulations of the Securities and Exchange Commission, national securities exchanges (including those located in countries outside of the United States) or the Nasdaq Stock Market; provided the disclosing Party discloses
only the minimum information required to be disclosed in order to comply with such requirements, including requesting confidential treatment of this Agreement (after consultation with the other Party) and filing this Agreement in redacted form.

 ARTICLE V 
 REPRESENTATIONS AND WARRANTIES 
 Section 5.01 Corporate Power. As of the Effective Date, each Party
hereby represents and warrants that such Party is duly organized and validly existing and in good standing under the laws of the jurisdiction of its incorporation and has full power and authority to enter into this Agreement and the transactions
contemplated hereby and to carry out the provisions hereof. 
 Section 5.02 Due Authorization. As of the Effective Date,
each Party hereby represents and warrants that such Party is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder. 
 Section 5.03 Binding Obligation. As of the Effective Date, each Party hereby represents and warrants that this Agreement is a legal and valid obligation binding upon it and is enforceable in
accordance with its terms, except that the enforcement of the rights and remedies created hereby is subject to bankruptcy, insolvency, reorganization and similar laws of general application affecting the rights and remedies of creditors and that the
availability of the remedy of specific performance or of injunctive relief is subject to the discretion of the court before which any proceeding therefor may be brought. As of the Effective Date, the execution, delivery and performance of this
Agreement by such Party (a) does not conflict with or violate (with or without notice, passage of time, or both) (i) any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound,
(ii) any provision of its certificate of incorporation, bylaws, or other governance documents or any resolution adopted by such Party’s Board of Directors or stockholders, or (iii) any law, regulation, order or requirement of any
court, governmental body or administrative or other agency having authority over it and (b) will not result in the imposition or creation of any Encumbrance upon or with respect to any of the Purchased Assets, except as contemplated by this
Agreement. Seller represents and warrants that, to its knowledge, it will not be required to make any filing with, give notice to, or obtain any consent or approval from any person, entity, or governmental body or other agency in connection with the
execution and delivery of this Agreement or other agreements and documents that are referenced herein or attached hereto as exhibit or the consummation of the transactions contemplated hereby and thereby, which if not obtained or made could
reasonably be expected to have a material adverse effect on the transactions contemplated by this Agreement. 
  

 10 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 Section 5.04 Ownership of Purchased Assets. As of the Effective Date, Seller
represents and warrants that it is the sole owner of all right, title and interest in and to the Purchased Assets, free and clear of all Encumbrances. 
 Section 5.05 Patent Proceedings. As of the Effective Date, Seller represents and warrants that to Seller’s actual knowledge, without having made an investigation or search, (a) no patent
or patent application within the BEMA Patent Rights is the subject of any pending interference, opposition, cancellation or other protest proceeding, (b) except with respect to matters previously disclosed to Seller by Buyer or its Affiliates,
there is no claim pending, previously made, or threatened alleging that the BEMA Technology, or the use, manufacture, sale, or importation of technology or products embodying the BEMA Technology, infringes or misappropriates any copyright, patent,
trade secret, trademark, or other published intellectual property right of any third party, (c) except with respect to matters previously disclosed to Seller by Buyer or its Affiliates, no prior use, manufacture, sale, or importation of the
BEMA Technology, or any technology or products embodying the foregoing by Seller, its Affiliates, or their Third Party licensees (excluding Seller’s grant of licenses under the License Agreement) constituted infringement or misappropriation of
any copyright, patent, trade secret, trademark, or other published intellectual property right of any Third Party, (d) all filings, payments, and other actions required to be made or taken to maintain such item of the BEMA Patent Rights in full
force and effect have been made by the applicable deadline, and (e) that it has complied, in all material respects, with its obligations under the License Agreement. For purposes of this Section 5.05, Seller’s actual knowledge shall
mean the actual knowledge, without having made an investigation or search, of Sean F. Moriarty, it being understood by the parties that Buyer has been responsible for maintaining and protecting the BEMA Patent Rights and the Marks since
August 16, 2006, except for the last two items on Exhibit A, for which, to the extent responsibility therefor has not previously been transferred to Buyer, such responsibility will be transferred no later than the Effective Date. 
 Section 5.06 Legal Proceedings. Except as noted below, as of the Effective Date, each Party hereby represents and warrants to the
other Party that there is no action, suit or proceeding pending against or affecting, or, to the knowledge of either Party, threatened against or affecting that Party, or any of its assets, before any court or arbitrator or any governmental body,
agency or official that would, if decided against either Party that would have a material adverse effect on that Party’s ability to consummate the transactions contemplated by this Agreement. 
 Section 5.07 Limitation on Warranties. Except as expressly set forth in this Agreement, nothing herein shall be construed as a
representation or warranty by Seller to Buyer that the BEMA Technology is not infringed by any Third Party, or that the practice of such rights does not infringe any published intellectual property rights of any Third Party. Neither Party makes any
warranties, express or implied, concerning the commercial utility of the Product. 
 Section 5.08 Limitation of Liability.
NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES (AS SUCH TERMS ARE DEFINED IN BLACK’S LAW DICTIONARY, SIXTH EDITION) IN CONNECTION WITH THIS AGREEMENT. 
  

 11 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 ARTICLE VI 
 COVENANTS 
 Section 6.01 Access to Books and Records. Upon five days prior
written notice from Seller, Buyer shall permit Seller or its representatives (which representatives shall be subject to the confidentiality provisions of the Agreement) to inspect those books and records (including but not limited to financial
records) as Seller deems necessary to ensure Buyer’s compliance with Section 6.02 of this Agreement. Buyer’s obligations under this Section 6.01 shall terminate three (3) months after Buyer’s payment in full of all
amounts due under the Secured Promissory Note. 
 Section 6.02 Commercially Reasonable Efforts. Buyer agrees to use
Commercially Reasonable Efforts to pursue Governmental Approval of the Product in the United States under Section 2.03(b)(i) of this Agreement. Buyer shall promptly advise Seller of any issues that materially and adversely affect its ability to
pursue Governmental Approval of the Product in the United States in accordance with Section 2.03(b)(i). Buyer’s obligations under this Section 6.02 shall terminate upon Buyer’s payment in full of all amounts due under the Secured
Promissory Note. 
 Section 6.03 Compliance. Buyer covenants and agrees that it shall comply, in all material respects,
with all Applicable Laws affecting the use, possession, distribution, advertising and promotion in connection with the sale and distribution of the Products and any demonstration samples. Buyer’s obligations under this Section 6.03 shall
terminate upon Buyer’s payment in full of all amounts due under the Secured Promissory Note. 
 Section 6.04 Further
Actions. Upon the terms and subject to the conditions hereof, each of the Parties hereto shall use its Commercially Reasonable Efforts to (a) take, or cause to be taken, all appropriate action and do, or cause to be done, all things
necessary, proper or advisable under Applicable Law or otherwise to consummate and make effective the transactions contemplated by this Agreement, (b) obtain from Competent Authorities any consents, licenses, permits, waivers, approvals,
authorizations or orders required to be obtained or made by the Parties in connection with the authorization, execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement and (c) make all
necessary filings, and thereafter make any other required submissions, with respect to this transaction under Applicable Law. The Parties hereto shall cooperate with each other in connection with the making of all such filings, including by
providing copies of all such documents to the other Party’s counsel (subject to appropriate confidentiality restrictions) prior to filing and, if requested, by accepting all reasonable additions, deletions or changes suggested in connection
therewith. Seller covenants that (i) in the event any Know-How or Patent Rights related to BEMA in the Territory come under its Control following the Effective Date, (1) it shall immediately notify Buyer and provide to Buyer all written
information related thereto and (2) subject to Buyer reimbursing Seller for any costs incurred by Seller following the Effective Date in obtaining such rights, such Know-How and Patent Rights shall be deemed Purchased Assets for purposes of
this Agreement and immediately assigned, free and clear of all liens, claims, and encumbrances (except with respect to such liens, claims or encumbrances existing on the date Seller obtained such rights), to Buyer, or if they cannot be so assigned,
included in the 

  

 12 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 
license granted in Section 2.02, and (ii) if Seller becomes aware of any Know-How or Patent Rights related to BEMA to which it has rights in the
Territory under the Pliva Agreement (as defined in the License Agreement), Pfizer Agreement (as defined in the License Agreement), or any other agreement, Seller shall (1) immediately notify Buyer in writing and provide to Buyer all written
information related thereto and (2) use Commercially Reasonable Efforts, as requested by Buyer, an at Buyer’s expense, which expense shall be commercially reasonable and documented, to obtain Control of such Know-How or Patent Rights for
purposes of assigning all right, title, and interest thereto to Buyer consistent with the foregoing, or if not so assignable, including in the license granted under Section 2.02. 
 ARTICLE VII 
 DELIVERIES 
 Section 7.01 Deliveries By Seller. On the Effective Date, Seller shall deliver, or cause to be delivered, the following items, duly
executed by Seller, as applicable: 
 (a) the Patent and Trademark Assignment Agreement; 
 (b) all Books and Records (which shall include but not be limited to those related to filing, prosecution, and/or maintenance of the BEMA
Patent Rights) and any actual filings or correspondence with any patent or trademark offices or agencies outside in the Territory; provided, however, that Seller shall be permitted to retain copies of the same for its internal records; 

(c) the Termination Agreement; and 
 (d) any other documents necessary to properly record the assignment to Buyer of all of Seller’s right, title and interest in and to the Purchased Assets. 
 Section 7.02 Deliveries By Buyer. On the Effective Date, Buyer shall deliver the following items, duly executed by Buyer: 

(a) the Closing Cash Payment; 
 (b) the Secured Promissory Note; 
 (c) the Security Agreement; 
 (d) the Patent and Trademark Security Agreement; 
 (e) the Guaranty (executed by BDSI); and 
 (f) the Termination Agreement (executed by Arius and CDC). 
  

 13 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 ARTICLE VIII 
 MISCELLANEOUS 
 Section 8.01 Governing Law. This Agreement shall be governed by,
and construed and enforced in accordance with, the laws of the State of New York (as permitted by Section 5-1401 of the New York General Obligations Law), without giving effect to any choice of law rule that would cause the application of the
laws of any jurisdiction other than the internal laws of the State of New York to the rights and duties of the Parties. 
 Section 8.02
Waiver. Except as specifically provided for herein, the waiver from time to time by either of the parties of any of their rights or their failure to exercise any remedy shall not operate or be construed as a continuing waiver of same
or of any other of such Party’s rights or remedies provided in this Agreement. 
 Section 8.03 Severability. In case
any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. Any provision of this Agreement held invalid or
unenforceable in part or degree will remain in full force and effect to the extent not held invalid or unenforceable. 
 Section 8.04
Notices. All notices and other communications provided for herein shall be dated and in writing and shall be deemed to have been duly given (a) on the date of delivery, if delivered personally, by e-mail or by facsimile machine,
receipt confirmed, (b) on the following business day, if delivered by a nationally recognized overnight courier service, with receipt acknowledgement requested, or (c) three business days after mailing, if sent by registered or certified
mail, return receipt requested, postage prepaid, in each case, to the party to whom it is directed at the following address (or at such other address as any party hereto shall hereafter specify by notice in writing to the other parties hereto):

  

			
	 If to Seller:
	  	QLT USA, Inc.
		  	2579 Midpoint Drive
		  	Fort Collins, CO 80525
		  	Attn: President
		  	Telephone: (970) 482-5868
		  	Facsimile: (970) 482-9735
		
	 Copies to:
	  	Morrison & Foerster LLP
		  	5200 Republic Plaza
		  	370 17th Street
		  	Denver, Colorado 80202-5638
		  	Attn: Warren L. Troupe, Esq.
		  	Telephone: (303) 592-2255
		  	Facsimile: (303) 592-1510

  

 14 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

			
		
	 If to Buyer:
	  	Arius Two, Inc.
		  	2501 Aerial Center Parkway, Suite 205
		  	Morrisville, North Carolina 27560
		  	Attn: Chief Executive Officer
		  	Facsimile: (919) 653-5161
		
	 Copies to:
	  	Wyrick Robbins Yates & Ponton LLP
		  	4101 Lake Boone Trail
		  	Suite 300
		  	Raleigh, North Carolina 27607-7506
		  	Attn: Larry E. Robbins, Esq.
		  	Telephone: (919) 781-4000
		  	Facsimile: (919) 781-4865

 Section 8.05 Independent Contractors. It is expressly agreed that the
relationship between the two Parties shall not constitute a partnership or agency of any kind. Neither Seller nor Buyer shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall
be binding on the other Party, without the prior written consent of the other Party. 
 Section 8.06 Rules of
Construction. The Parties hereto agree that they have been represented by counsel during the negotiation and execution of this Agreement and, therefore, waive the application of any law, regulation, holding or rule of construction providing
that ambiguities in an agreement or other document will be construed against the Party drafting such agreement or document. Whenever the context hereof shall so require, the singular shall include the plural, the male gender shall include the female
gender and neuter, and vice versa. 
 Section 8.07 Publicity. Subject to Section 4.02, Buyer and Seller shall consult
with each other before issuing any press release with respect to this Agreement or the transactions contemplated hereby and neither shall issue any such press release or make any such public statement without the prior consent of the other, which
consent shall not be unreasonably withheld; provided, however, (a) that a Party may, without the prior consent of the other Party, issue such press release or make such public statement as may upon the advice of counsel be required by law or
the rules and regulations of the Nasdaq or any other stock exchange, or (b) if it has used reasonable efforts to consult with the other Party prior thereto, (such consent shall be deemed to have been given if the recipient of the press release
or public statement fails to respond to the other Party within 48 hours after the recipient’s receipt of such press release or public statement). No such consent of the other Party shall be required to release information which has previously
been made public. 
 Section 8.08 Entire Agreement; Amendment. This Agreement (including the Exhibits attached hereto)
sets forth all of the covenants, promises, agreements, warranties, representations, conditions and understandings between the parties hereto with respect to the subject matter hereof and supersedes and terminates all prior agreements and
understandings between the Parties. There are no covenants, promises, agreements, warranties, representations 

  

 15 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 
conditions or understandings, either oral or written, between the parties other than as set forth herein. No subsequent alteration, amendment, change or
addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. 
 Section 8.09 Headings. The captions contained in this Agreement are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the several Articles hereof.

 Section 8.10 Waiver of Jury Trial. THE PARTIES HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A TRIAL BY JURY OF ANY CLAIM OR
CAUSE OF ACTION BASED UPON OR ARISING OUT OF OR RELATED TO THIS AGREEMENT. 
 Section 8.11 Counterparts. This Agreement
may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Signatures to this Agreement may be transmitted via facsimile and such signatures shall
be deemed to be originals. 
 Section 8.12 Assignment. Neither Party may assign, sell, hypothecate or otherwise transfer
any interest in or obligation under this Agreement without the prior written consent of the other Party; provided that, notwithstanding the foregoing, either Party shall be entitled to assign, sell, hypothecate, or transfer its interest in or
obligations under this Agreement without such consent (i) to any Affiliate or (ii) in connection with any sale of substantially all of its assets or business (or portion of its assets or business related to the subject matter hereof),
merger, acquisition, consolidation, or other similar transaction. Notwithstanding the foregoing, any such assignment shall not relieve the assigning Party of its responsibilities for performance of its obligations under this Agreement. 

[Signature page to follow.] 
  

 16 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed in duplicate by
their duly authorized officers as of the Effective Date. 
  

			
	ARIUS TWO, INC.,
	a Delaware corporation
		
	By:	 	 /s/ Mark A. Sirgo

	Name:	 	Mark A. Sirgo
	Title:	 	President
	
	 QLT USA, INC.,
 a Delaware
corporation

		
	By:	 	 /s/ Michael R. Duncan

	Name:	 	Michael R. Duncan
	Title:	 	President

  

 17 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 EXHIBIT A 
 BEMA PATENT RIGHTS 
  

											
	 App. No./
 Patent No.
	  	 Filing Date/
 Issue Date
	  	 Country
	  	 Title
	  	 Status
	  	 Attorney
 Docket No.

	 08/734,519
 5,800,832
	  	 18-Oct-1996
 01-Sep-1998
	  	US	  	Bioerodable Film For Delivery Of Pharmaceutical Compounds To Mucosal Surfaces	  	Granted	  	092
						
	 09/144,827
 6,159,498
	  	 01-Sep-1998
 12-Dec-2000
	  	US	  	Same As Above	  	Granted	  	092CN
						
	PCT/US97/18605	  	16-Oct-1997	  	US	  	Pharmaceutical Carrier Device Suitable For Delivery Of Pharmaceutical Compounds To Mucosal Surfaces	  	Nationalized	  	092PC
						
	09/069,703	  	29-Apr-1998	  	US	  	Same As Above	  	Pending	  	092CPRCE
						
	09/684,682	  	04-Oct-2000	  	US	  	Same As Above	  	Abandoned	  	092CPDVRCE
						
	10/962,833	  	12-Oct-2004	  	US	  	Same As Above	  	Pending	  	092CPDVCN
						
	11/069,089	  	01-Mar-2005	  	US	  	Same As Above	  	Pending	  	092CPDVCN2
						
	PCT/US99/09378	  	29-Apr-1999	  	PCT	  	Same As Above	  	Nationalized	  	093CPPC
						
	60/495,356	  	15-Aug-2003	  	US	  	Adhesive Bioerodible Transmucosal Drug Delivery System	  	Expired	  	093-1
						
	PCT/US04/026531	  	16-Aug-2004	  	PCT	  	Same As Above	  	Nationalized	  	093PC
						
	11/355,312	  	15-Feb-2006	  	US	  	Same As Above	  	Pending	  	093CN
						
	11/645,091	  	22-Dec-2006	  	US	  	Same As Above	  	Pending	  	093CN2
						
	10/121,430	  	11-Apr-2002	  	US	  	Process For Loading A Drug Delivery Device	  	Abandoned	  	094
						
	PCT/US03/11313	  	11-Apr-2003	  	PCT	  	Same As Above	  	Abandoned	  	094PC
						
	60/441,829	  	22-Jan-2003	  	US	  	Bioerodable Film For Delivery Of Pharmaceutical Compounds To Mucosal Surfaces	  	Expired	  	095-1
						
	10/763,063	  	22-Jan-2004	  	US	  	Same As Above	  	Unknown	  	095

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 EXHIBIT B 
 GUARANTY 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 EXHIBIT C 
 PATENT AND TRADEMARK ASSIGNMENT AGREEMENT 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 EXHIBIT D 
 PATENT AND TRADEMARK SECURITY AGREEMENT 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 EXHIBIT E 
 SECURED PROMISSORY NOTE 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 EXHIBIT F 
 SECURITY AGREEMENT 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 EXHIBIT G 
 TERMINATION AGREEMENTAmended  and Restated Patent and Trademark Security Agreement

 Exhibit 10.6 
 AMENDED AND RESTATED 
 PATENT AND TRADEMARK SECURITY AGREEMENT 
 This AMENDED AND RESTATED PATENT AND TRADEMARK SECURITY AGREEMENT (this “Agreement”), dated as of September 5, 2007, is entered into
between Arius Two, Inc., a Delaware corporation (“Grantor”), which has a mailing address at 2501 Aerial Center Parkway, Suite 205, Morrisville, North Carolina 25760, and QLT USA, Inc., a Delaware corporation (“Lender”), having
its principal executive office at 2579 Midpoint Drive, Fort Collins, Colorado 80525. 
 RECITALS 
 A. The Grantor, as borrower, and the Lender have entered into that certain Intellectual Property Assignment Agreement dated as of September 5, 2007
(the “Transfer Agreement”) and Secured Promissory Note dated as of September 5, 2007 (the “Note”) (all capitalized terms used in this Agreement and not otherwise defined herein having the meanings assigned to them in the
Transfer Agreement); 
 B. Grantor is the owner of certain intellectual property, identified below, in which Grantor has previously granted a
security interest to Lender under that certain Patent and Trademark Security Agreement, dated September 5, 2007 (the “Original Agreement”); 
 C. The parties wish to amend and restate the Original Agreement as described herein. 
 NOW THEREFORE, the
parties hereto mutually agree as follows: 
 0. AMENDMENT AND RESTATEMENT. The parties hereby agree that the Original Agreement shall be hereby amended
and restated in its entirety as described herein. 
 1. GRANT OF SECURITY INTEREST. 
 To secure the complete and timely payment and performance of all Obligations (as defined in the Amended and Restated Security Agreement, dated as of
September 5, 2007, between the Grantor and the Lender concerning certain assets in the United States, Canada, and Mexico (the “Security Agreement”)), and without limiting any other security interest Grantor has granted to Lender, Grantor
hereby grants, assigns, and conveys to Lender a security interest in Grantor’s entire right, title, and interest, whether now owned or hereafter acquired, in and to the following (the “Collateral”): 
 (i) All of Grantor’s right to (a) the Marks, (b) the Ex-US BEMA Marks (as defined in that certain Intellectual Property
Assignment Agreement, dated August 2, 2006, between the parties (the “Ex-US Purchase Agreement”)) concerning Canada and Mexico (the “North American Territory”), (c) trademark registrations related to any of the
foregoing, including but not limited to those listed on Exhibit A, as the same 

 
may be updated hereafter from time to time, and (d) all trademark rights with respect thereto throughout the North American Territory, including all
proceeds thereof (including license royalties and proceeds of infringement suits), and rights to renew and extend such trademarks and trademark rights; 
 (ii) All of Grantor’s right, title, and interest, in and to (a) BEMA Patent Rights, (b) the Ex-US BEMA Patent Rights (as defined in the Ex-US Purchase Agreement) concerning the North American Territory,
including but not limited to, with respect to (a) and (b), those listed on Exhibit B, as the same may be updated hereafter from time to time, and (c) all patent rights with respect thereto throughout the North American Territory,
including all proceeds thereof (including license royalties and proceeds of infringement suits), foreign filing rights, and rights to extend such patents and patent rights; 
 (iii) the entire goodwill of or associated with the businesses now or hereafter conducted by Grantor connected with and symbolized by any
of the aforementioned properties and assets; 
 (iv) all commercial tort claims associated with or arising out of any of the
aforementioned properties and assets; 
 (v) all accounts, all intangible intellectual or other similar property and other
general intangibles associated with or arising out of any of the aforementioned properties and assets and not otherwise described above, including all license payments and payments under insurance (whether or not the Lender is the loss payee
thereof) or any indemnity, warranty or guaranty payable by reason of loss or damage to or otherwise with respect to the foregoing Collateral; and 
 (vi) All products, proceeds and supporting obligations of or with respect to any and all of the foregoing Collateral. 
 2. AFTER-ACQUIRED PATENT OR TRADEMARK RIGHTS. 
 If Grantor shall obtain rights to any new trademarks, any new patentable
inventions or become entitled to the benefit of any patent application or patent for any reissue, division, or continuation, of any patent, in each case in the North American Territory and in connection with, derived from, or arising out of, the
BEMA Technology, the Marks, the Products, or, to the extent concerning the North American Territory or any country therein, the Ex-US BEMA Marks, the Ex-US BEMA Patent Rights, or the Ex-US Products (each as defined in the Ex-US Purchase Agreement),
the provisions of this Agreement shall automatically apply thereto. Grantor shall give prompt notice in writing to Lender with respect to any such new trademarks or patents, or renewal or extension of any trademark registration. Without limiting
Grantor’s obligation under this Section 2, Grantor authorizes Lender to modify this Agreement by amending Exhibits A or B to include any such new patent or trademark rights. Notwithstanding the foregoing, no failure to so modify
this Agreement or amend Exhibits A or B shall in any way affect, invalidate or detract from Lender’s continuing security interest in all Collateral, whether or not listed on Exhibit A or B. 
  

 2 

 3. GENERAL PROVISIONS. 
 3.1 Rights Under Security Agreement. This Agreement has been granted in conjunction with the security interest granted to Lender under the Security Agreement. The rights and remedies of Lender with respect to
the security interests granted herein are without prejudice to, and are in addition to those set forth in the Security Agreement, all terms and provisions of which are incorporated herein by reference. 
 3.2 Successors. The benefits and burdens of this Agreement shall inure to the benefit of and be binding upon the respective successors and
permitted assigns of the parties; provided that Grantor may not transfer any of the Collateral or any of its rights or obligations hereunder, without the prior written consent of Lender, except as specifically permitted by the Note or the Security
Agreement. 
 3.3 Amendment; No Conflict. This Agreement is subject to modification only by a writing signed by the parties, except as
provided in Section 2 of this Agreement. To the extent that any provision of this Agreement conflicts with any provision of the Security Agreement, the provision giving Lender greater rights or remedies shall govern, it being understood that
the purpose of this Agreement is to add to, and not detract from, the rights granted to Lender under the Security Agreement. 
 3.4
Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York (as permitted by Section 5-1401 of the New York General Obligations Law), without giving effect to any
choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of New York to the rights and duties of the parties, except as required by mandatory provisions of law and to the extent
the validity or perfection of the security interests hereunder, or the remedies hereunder, in respect of any Collateral are governed by the law of a jurisdiction other than New York. 
 3.5 Waiver of Jury Trial. THE GRANTOR AND, BY ITS ACCEPTANCE HEREOF, THE LENDER, HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A TRIAL BY JURY OF ANY
CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF OR RELATED TO THIS AGREEMENT. 
 4. TERMINATION. Upon payment and performance in full of all
Obligations (as defined in that certain Security Agreement between the parties of even date herewith), the security interest created under this Agreement shall terminate and Lender shall promptly execute and deliver to Grantor such documents and
instruments reasonably requested by Grantor as shall be necessary to evidence termination of all security interests given by Grantor to Lender hereunder. 
 [Signature page to follow.] 
  

 3 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the date first written above. 

 

									
	QLT USA, INC.	 		 	ARIUS TWO, INC.
					
	By:	 	 /s/ Michael R. Duncan
	 		 	By:	 	 /s/ Mark Sirgo

	Name:	 	Michael R. Duncan	 		 		 	Mark Sirgo, Chief Executive Officer
	Title:	 	President	 		 		 	

  

 4 

 Exhibit A 
 MARKS 
 BEMA in the United States (and its territories and possessions, including but not limited to
the Commonwealth of Puerto Rico), Canada, and Mexico, and including but not limited to the following: 
  

							
	 COUNTRY
	 	 APPLICATION NO./
 FILING DATE
	 	 REGISTRATION NO./
 REGISTRATION DATE
	 	 EXPIRATION/
 RENEWAL DATE

	 United States
	 	 78424675
 May 25, 2004
	 	Pending	 	
				
		 		 		 	

  

 1 

 Exhibit B 
 PATENTS AND PATENT APPLICATIONS 
  

											
	 App. No./
 Patent No.
	 	 Filing Date/
 Issue Date
	 	 Country
	 	 Title
	 	 Status
	 	 Attorney
 Docket No.

	08/734,519
 5,800,832
	 	18-Oct-1996
 01-Sep-1998
	 	US	 	Bioerodable Film For Delivery Of Pharmaceutical Compounds To Mucosal Surfaces	 	Granted	 	092
						
	09/144,827
 6,159,498
	 	01-Sep-1998
 12-Dec-2000
	 	US	 	Same As Above	 	Granted	 	092CN
						
	09/069,703	 	29-Apr-1998	 	US	 	Pharmaceutical Carrier Device Suitable For Delivery Of Pharmaceutical Compounds To Mucosal Surfaces	 	Pending	 	092CPRCE
						
	09/684,682	 	04-Oct-2000	 	US	 	Same As Above	 	Abandoned	 	092CPDVRCE
						
	10/962,833	 	12-Oct-2004	 	US	 	Same As Above	 	Published	 	092CPDVCN
						
	11/069,089	 	01-Mar-2005	 	US	 	Same As Above	 	Published	 	092CPDVCN2
						
	2,268,187
 2,268,187
	 	16-Oct-1997
 05-Jun-2007
	 	CA	 	Bioerodable Film For Delivery Of Pharmaceutical Compounds To Mucosal Surfaces	 	Granted	 	092CA
						
	2,329,128	 	29-Apr-1999	 	CA	 	Pharmaceutical Carrier Device Suitable For Delivery Of Pharmaceutical Compounds To Mucosal Surfaces	 	Pending	 	092PC2CA
						
	60/495,356	 	15-Aug-2003	 	US	 	 Adhesive Bioerodible Transmucosal Drug
 Delivery System

	 	Expired	 	093-1
						
	PCT/US04/0
 26531
	 	16-Aug-2004	 	PCT	 	Same As Above	 	Nationalized	 	093PC
						
	11/355,312	 	15-Feb-2006	 	US	 	Same As Above	 	Pending	 	093CN
						
	11/645,091	 	22-Dec-2006	 	US	 	Same As Above	 	Pending	 	093CN2
						
	2,535,846	 	16-Aug-2004	 	CA	 	Same As Above	 	Pending	 	093CA
						
	PA/a/2006/0
 01776
	 	16-Aug-2004	 	MX	 	Same As Above	 	Pending	 	093MX
						
	10/121,430	 	11-Apr-2002	 	US	 	Process For Loading A Drug Delivery Device	 	Abandoned	 	094
						
	PCT/US03/1
 1313
	 	11-Apr-2003	 	PCT	 	Same As Above	 	Abandoned	 	094PC
						
	60/441,829	 	22-Jan-2003	 	US	 	Bioerodable Film For Delivery Of Pharmaceutical Compounds To Mucosal	 	Expired	 	095-1

											
	 App. No./
 Patent No.
	 	 Filing Date/
 Issue Date
	 	 Country
	 	 Title
	 	 Status
	 	 Attorney
 Docket No.

		 		 		 	Surfaces	 		 	
						
	10/763,063	 	22-Jan-2004	 	US	 	Bioerodable Film For Delivery Of Pharmaceutical Compounds To Mucosal Surfaces	 	Unknown	 	095

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]